SLC6A3 and Parkinson disease: One possible explanation in these cases is the subclinical drug-exacerbated parkinsonism, in which the individual develops parkinsonism with a symmetrical abnormality in DAT and neurologic examination after a short term of the medication, mainly dopamine-blocking agents.